Search clinical trials for: Filgotinib placebo

Total 53638 results

Gilead Sciences
Galapagos NV

Completed

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus

United States, Canada
Galapagos NV
Gilead Sciences

Active, not recruiting

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (FINCH 4)

Rheumatoid Arthritis

Spain, United States, Japan, Korea, Republic of, Taiwan, Belgium, India, Malaysia, Argentina, Australia, Poland, Czechia, Serbia, Germany, New Zealand, Bulgaria, Canada, Chile, France, Hong Kong, Hungary, Ireland, Israel, Italy, Mexico, R... and more
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Lupus Membranous Nephropathy

United States
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease (Divergence2)

Fistulizing Crohn's Disease

United States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) (DIVERGENCE 1)

Small Bowel Crohn's Disease

United States, Belgium, United Kingdom, Germany, Spain, Czechia, Canada, Austria, France, Hungary, Italy, Ukraine
Gilead Sciences
Ono Pharmaceutical Co. Ltd; Galapagos NV

Completed

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Sjogren's Syndrome

United States, Spain, United Kingdom, Poland
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis (TORTUGA)

Ankylosing Spondylitis

Belgium, Bulgaria, Czechia, Estonia, Poland, Spain, Ukraine
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Galapagos NV

Terminated

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission (CAPYBARA)

Ulcerative Colitis

United States, Germany, Korea, Republic of, Spain, France, Hungary, United Kingdom, Poland, Belgium, Czechia, Italy, South Africa, Taiwan
Galapagos NV

Recruiting

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (OLINGUITO)

Axial Spondyloarthritis

Belgium, Korea, Republic of, Germany, Netherlands, France, Taiwan, Greece, United Kingdom, Italy, Bulgaria, South Africa, Estonia, Spain, Hungary, Czechia, Lithuania, Philippines, Poland, Romania, Croatia
Galapagos NV
Gilead Sciences

Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (DIVERSITY1)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, France, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, United Kingdom, Italy, India, Singapore, Portugal, Malaysia, New Zealand, Serbia, Ireland, Poland, Romania, Japan, ... and more
Galapagos NV
Gilead Sciences

Terminated

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (DIVERSITYLTE)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, Italy, India, Singapore, Portugal, France, Malaysia, New Zealand, Ireland, Poland, Romania, Japan, Croatia, Iceland, United... and more
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION1-IR)

Ankylosing Spondylitis
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION2-NAÏVE)

Ankylosing Spondylitis
Galapagos NV
Gilead Sciences

Active, not recruiting

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Australia, Italy, Hong Kong, Singapore, Korea, Republic of, Canada, Germany, United Kingdom, New Zealand, Ireland, Poland, Romania, Croatia, Belgium, Japan, India, Malaysia, Sweden, F... and more
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis (SELECTION)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Germany, Australia, Italy, Hong Kong, India, Singapore, Canada, Korea, Republic of, United Kingdom, New Zealand, Ireland, France, Poland, Japan, Switzerland, Croatia, Belgium, Malaysia and more
Georgetown University

Unknown

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib)

Parkinson Disease | Parkinsons Disease With Dementia

United States
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
Galapagos NV
Gilead Sciences

Completed

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis (MANTA-RAy)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis | Non-Radiographical Axial Spondyloarthritis

Bulgaria, Ukraine, Poland, Estonia, Czechia, Georgia, Latvia, Spain
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Gilead Sciences
Galapagos NV

Completed

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy (FINCH 3)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Korea, Republic of, Japan, Australia, Chile, Russian Federation, Argentina, Germany, New Zealand, Th... and more
UMC Utrecht
Alfasigma S.p.A.; ReumaNederland; Autoimmune Research and Collaboration Hub

Not yet recruiting

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases (DRIMID)

IgG4-related Disease | Idiopathic Inflammatory Myopathies | Behcet's Disease

Netherlands
Galapagos NV

Recruiting

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) (GALOCEAN)

Ulcerative Colitis

Belgium, Netherlands, France, Italy, Germany, Norway, United Kingdom, Ireland, Austria
Galapagos NV

Recruiting

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis (FILOSOPHY)

Rheumatoid Arthritis

Belgium, Germany, Spain, Italy, United Kingdom, Netherlands
Galapagos NV

Recruiting

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France (PARROTFISH)

Rheumatoid Arthritis

France
Gilead Sciences
Galapagos NV

Completed

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (FINCH 1)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Israel, Bulgaria, India, Serbia, South Africa, Korea, Republic of, Japan, Russian Federation, Argentina, Germany, New Zealand, Thailand, Hungary, Netherlands, Slovaki... and more
Georgetown University
National Institutes of Health (NIH)

Recruiting

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

Rheumatoid Arthritis

United States, Germany, New Zealand
Galapagos NV

Recruiting

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Juvenile Idiopathic Arthritis

Spain, Germany, United Kingdom, France, Poland
Galapagos NV

Completed

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Bioavailability

Canada
Gilead Sciences
Galapagos NV

Completed

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment (FINCH 2)

Rheumatoid Arthritis

United States, France, Germany, Spain, Israel, Japan, Korea, Republic of, Belgium, Argentina, Poland, Hungary, United Kingdom, Mexico, Australia, Switzerland
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (HUMBOLDT)

Noninfectious Uveitis

United States, Israel, United Kingdom, Germany, Australia, Canada, New Zealand
Northwestern University
University of Iowa; University of Rochester; Michael J. Fox Foundation for Parkinson...

Completed

Nilotinib in Parkinson's Disease (NILO-PD)

Parkinson Disease

United States
Galapagos NV
Gilead Sciences

Terminated

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease (MANTA)

Inflammatory Bowel Disease

United States, Australia, India, Germany, United Kingdom, Russian Federation, New Zealand, Austria, Poland, Romania, Ukraine
Georgetown University

Unknown

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

United States
XSpray Microparticles

Completed

Pharmacokinetic Comparison of XS003 and Tasigna

Healthy

United Kingdom
Shenzhen Second People's Hospital
Dongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaborators

Recruiting

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Chronic Myeloid Leukemia, Chronic Phase | Nilotinib

China
Andrew J. Wagner, MD, PhD
Massachusetts General Hospital; Novartis; Brigham and Women's Hospital

Active, not recruiting

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell Tumor

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With HES

Hypereosinophilic Syndrome (HES)
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals

Completed

Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers

Healthy
Sheba Medical Center

Completed

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Stem Cell Transplantation | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Israel
Samsung Medical Center

Completed

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Metastatic Melanoma With KIT Aberration

Korea, Republic of
University of Colorado, Denver
POM Wonderful LLC

Completed

Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
University Health Network, Toronto
Novartis

Terminated

A Study of Nilotinib in Growing Vestibular Schwannomas

Growing Vestibular Schwannomas

Canada

Search clinical trials for: Filgotinib placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations